Both Hoth Therapeutics Inc. (NASDAQ:HOTH) and Denali Therapeutics Inc. (NASDAQ:DNLI) are each other’s competitor in the Biotechnology industry. Thus the contrast of their analyst recommendations, profitability, risk, dividends, institutional ownership, earnings and valuation.
Earnings and Valuation
|Gross Revenue||Price/Sales Ratio||Net Income||Earnings Per Share||Price/Earnings Ratio|
|Hoth Therapeutics Inc.||N/A||0.00||2.50M||-0.24||0.00|
|Denali Therapeutics Inc.||132.72M||14.97||51.55M||-1.45||0.00|
Table 1 shows the top-line revenue, earnings per share and valuation for Hoth Therapeutics Inc. and Denali Therapeutics Inc.
Table 2 shows us Hoth Therapeutics Inc. and Denali Therapeutics Inc.’s return on equity, net margins and return on assets.
|Net Margins||Return on Equity||Return on Assets|
|Hoth Therapeutics Inc.||0.00%||0%||0%|
|Denali Therapeutics Inc.||-38.84%||-27.9%||-24.7%|
Insider and Institutional Ownership
The shares of both Hoth Therapeutics Inc. and Denali Therapeutics Inc. are owned by institutional investors at 0% and 84.5% respectively. Insiders held 26.59% of Hoth Therapeutics Inc. shares. Insiders Competitively, held 0.1% of Denali Therapeutics Inc. shares.
Here are the Weekly, Monthly, Quarterly, Half Yearly, Yearly and YTD Performance of both pretenders.
|Performance (W)||Performance (M)||Performance (Q)||Performance (HY)||Performance (Y)||Performance (YTD)|
|Hoth Therapeutics Inc.||-8.99%||0%||0%||0%||0%||-31.18%|
|Denali Therapeutics Inc.||-0.05%||15.48%||14.34%||22.14%||2.04%||6.53%|
For the past year Hoth Therapeutics Inc. had bearish trend while Denali Therapeutics Inc. had bullish trend.
Hoth Therapeutics Inc. beats on 5 of the 9 factors Denali Therapeutics Inc.
Denali Therapeutics Inc., a biopharmaceutical company, engages in discovering and developing therapeutics for neurodegenerative diseases in the United States. The company's lead LRRK2 product candidates includes the DNL201, a small molecule inhibitor that is in Phase I clinical trials, as well as DNL151, a small molecule inhibitor, which is in preclinical development stage for the treatment of Parkinson's disease. It is also developing therapeutics for the treatment of Parkinson's, dementia with Lewy bodies, and multiple system atrophy; amyotrophic lateral sclerosis; and mucopolysaccharidosis type II patients. Denali Therapeutics Inc. has collaboration agreement with Takeda Pharmaceutical Company to develop and commercialize therapeutic product candidates for neurodegenerative diseases; and a strategic partnership with Lonza Pharma & Biotech to develop and produce biologic medicines for neurodegenerative diseases. The company was formerly known as SPR Pharma Inc. and changed its name to Denali Therapeutics Inc. in March 2015. Denali Therapeutics Inc. was incorporated in 2013 and is headquartered in South San Francisco, California.